IMNM
Immunome, Inc. [IMNM] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
IMNM Stock Summary
Top 10 Correlated ETFs
IMNM
Top 10 Correlated Stocks
IMNM
In the News
IMNM Financial details
Company Rating
Neutral
Market Cap
879.38M
Income
-22.38M
Revenue
10.19M
Book val./share
0.5
Cash/share
7.43
Dividend
-
Dividend %
-
Employees
37
Optionable
No
Shortable
Yes
Earnings
14 Mar 2024
P/E
-6.54
Forward P/E
-
PEG
4.95
P/S
50.31
P/B
24.1
P/C
2.12
P/FCF
193.2
Quick Ratio
3.92
Current Ratio
3.96
Debt / Equity
0.06
LT Debt / Equity
0.02
-
-
EPS (TTM)
-1.84
EPS next Y
-
EPS next Q
-
EPS this Y
45.75%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-16.37%
EPS Q/Q
-21.74%
-
-
-
-
SMA20
-17.39%
SMA50
-5%
SMA100
137.5%
Inst Own
16.92%
Inst Trans
1.07%
ROA
-24%
ROE
-195%
ROC
-0.32%
Gross Margin
100%
Oper. Margin
-222%
Profit Margin
-220%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
4.44-30.958
52W High
-47.6%
52W Low
+293%
RSI
27
Rel Volume
1.48
Avg Volume
747.88K
Volume
1.11M
Perf Week
-25.21%
Perf Month
-40.95%
Perf Quarter
80.07%
Perf Half Y
79.66%
-
-
-
-
Beta
1.557
-
-
Volatility
1.43%, 2.64%
Prev Close
-8.5%
Price
15.72
Change
-9.34%
IMNM Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -1.79 | -1.84 | -5.05 | -2.12 | -3.09 | |
| Operating cash flow per share | -1.69 | -1.67 | -3.58 | -1.58 | -2.37 | |
| Free cash flow per share | -1.74 | -1.71 | -3.75 | -1.59 | -2.39 | |
| Cash per share | 0.36 | 0.44 | 11.73 | 4.27 | 1.68 | |
| Book value per share | -5.74 | -6.2 | 12.2 | 4.18 | 1.37 | |
| Tangible book value per share | -5.74 | -6.2 | 12.2 | 4.18 | 1.37 | |
| Share holders equity per share | -5.74 | -6.2 | 12.2 | 4.18 | 1.37 | |
| Interest debt per share | 0.3 | 0.12 | 0.19 | 0.03 | 0.02 | |
| Market cap | 59.04M | 77.26M | 32.81M | 149.54M | 26.8M | |
| Enterprise value | 58.62M | 75.28M | -6.34M | 100.63M | 6.77M | |
| P/E ratio | -7.53 | -7.32 | -1.92 | -6.11 | -0.71 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -7.97 | -8.05 | -2.7 | -8.2 | -0.93 | |
| PFCF ratio | -7.73 | -7.86 | -2.58 | -8.17 | -0.93 | |
| P/B Ratio | -2.34 | -2.17 | 0.79 | 3.1 | 1.61 | |
| PTB ratio | -2.34 | -2.17 | 0.79 | 3.1 | 1.61 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -8.16 | -7.74 | 0.52 | -4.07 | -0.19 | |
| EV to operating cash flow | -7.91 | -7.84 | 0.52 | -5.52 | -0.24 | |
| EV to free cash flow | -7.68 | -7.66 | 0.5 | -5.5 | -0.23 | |
| Earnings yield | -0.13 | -0.14 | -0.52 | -0.16 | -1.4 | |
| Free cash flow yield | -0.13 | -0.13 | -0.39 | -0.12 | -1.08 | |
| Debt to equity | -0.05 | -0.02 | 0.01 | 0.01 | 0.02 | |
| Debt to assets | 0.26 | 0.11 | 0.01 | 0.01 | 0.01 | |
| Net debt to EBITDA | 0.06 | 0.2 | 3.19 | 1.98 | 0.55 | |
| Current ratio | 1.35 | 1.88 | 14.12 | 5.82 | 3.09 | |
| Interest coverage | -54.91 | -97.62 | -322.66 | -2.52K | -7.38K | |
| Income quality | 0.94 | 0.92 | 0.68 | 0.74 | 0.78 | |
| Dividend Yield | 0 | 0.06 | 0 | 0 | 0 | |
| Payout ratio | 0 | -0.44 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.03 | 0.02 | 0.05 | 0 | 0.01 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.44 | -0.38 | -0.78 | -0.1 | -0.39 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 15.19 | 16.01 | 37.23 | 14.12 | 9.78 | |
| ROIC | 0.33 | 0.3 | -0.28 | -0.51 | -2.18 | |
| Return on tangible assets | -1.76 | -2.08 | -0.38 | -0.42 | -1.56 | |
| Graham Net | -6.39 | -6.64 | 10.86 | 3.52 | 1.08 | |
| Working capital | 550K | 1.46M | 39.86M | 46.91M | 15.32M | |
| Tangible asset value | -25.21M | -35.63M | 41.35M | 48.19M | 16.65M | |
| Net current asset value | -27.54M | -37.57M | 39.71M | 46.9M | 15.26M | |
| Invested capital | -0.05 | -0.02 | 0.01 | 0.01 | 0.02 | |
| Average receivables | 0 | 0 | 450K | 2.61M | 2.58M | |
| Average payables | 0 | 510.5K | 867.5K | 2.13M | 2.74M | |
| Average inventory | 0 | 0 | -450K | -2.61M | -2.58M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 325.24 | 573.85 | 1.49K | 1.39K | |
| Days of inventory on hand | 0 | 0 | -435.1 | -2.08K | -489.94 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 1.12 | 0.64 | 0.25 | 0.26 | |
| Inventory turnover | 0 | 0 | -0.84 | -0.18 | -0.74 | |
| ROE | 0.31 | 0.3 | -0.41 | -0.51 | -2.25 | |
| Capex per share | -0.05 | -0.04 | -0.17 | -0.01 | -0.02 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0.19 | 0.35 | 0.29 | |
| Net income per share | -0.7 | -0.69 | -0.33 | -0.46 | -0.36 | |
| Operating cash flow per share | -0.62 | -0.55 | 1.98 | -0.46 | -0.71 | |
| Free cash flow per share | -0.62 | -0.56 | 1.98 | -0.49 | -0.71 | |
| Cash per share | 2.23 | 1.68 | 3.65 | 3.15 | 7.43 | |
| Book value per share | 1.9 | 1.37 | 1.14 | 0.77 | 0.5 | |
| Tangible book value per share | 1.9 | 1.37 | 1.14 | 0.77 | 0.5 | |
| Share holders equity per share | 1.9 | 1.37 | 1.14 | 0.77 | 0.5 | |
| Interest debt per share | 0.02 | 0.02 | 0 | 0.04 | 0.03 | |
| Market cap | 53.85M | 26.8M | 60.79M | 96.48M | 101.89M | |
| Enterprise value | 26.95M | 6.77M | 16.6M | 58.56M | 11.62M | |
| P/E ratio | -1.58 | -0.8 | -3.73 | -4.34 | -5.86 | |
| Price to sales ratio | 0 | 0 | 25.72 | 22.63 | 28.58 | |
| POCF ratio | -7.11 | -4.01 | 2.51 | -17.02 | -11.83 | |
| PFCF ratio | -7.11 | -3.97 | 2.53 | -16.06 | -11.78 | |
| P/B Ratio | 2.33 | 1.61 | 4.39 | 10.33 | 16.77 | |
| PTB ratio | 2.33 | 1.61 | 4.39 | 10.33 | 16.77 | |
| EV to sales | 0 | 0 | 7.02 | 13.74 | 3.26 | |
| Enterprise value over EBITDA | -3.2 | -0.9 | -3.71 | -10.43 | -2.51 | |
| EV to operating cash flow | -3.56 | -1.01 | 0.69 | -10.33 | -1.35 | |
| EV to free cash flow | -3.56 | -1 | 0.69 | -9.75 | -1.34 | |
| Earnings yield | -0.16 | -0.31 | -0.07 | -0.06 | -0.04 | |
| Free cash flow yield | -0.14 | -0.25 | 0.4 | -0.06 | -0.08 | |
| Debt to equity | 0.01 | 0.02 | 0.02 | 0.05 | 0.06 | |
| Debt to assets | 0.01 | 0.01 | 0 | 0.01 | 0 | |
| Net debt to EBITDA | 3.19 | 2.66 | 9.88 | 6.75 | 19.48 | |
| Current ratio | 3.97 | 3.09 | 1.87 | 1.5 | 3.96 | |
| Interest coverage | -8.53K | -1.95K | 22.24 | 0 | 0 | |
| Income quality | 0.89 | 0.86 | -5.66 | 1.02 | 1.98 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 1.24 | 1.01 | 1.23 | |
| Research and developement to revenue | 0 | 0 | 1.66 | 1.34 | 1.07 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0.01 | 0 | 0.06 | 0 | |
| Capex to revenue | 0 | 0 | -0.04 | -0.08 | -0.01 | |
| Capex to depreciation | 0 | -0.28 | -0.72 | -2.17 | -0.22 | |
| Stock based compensation to revenue | 0 | 0 | 0.52 | 0.24 | 0.3 | |
| Graham number | 5.49 | 4.63 | 2.92 | 2.8 | 2 | |
| ROIC | -0.36 | -0.49 | -0.3 | -0.56 | -0.65 | |
| Return on tangible assets | -0.28 | -0.35 | -0.08 | -0.13 | -0.05 | |
| Graham Net | 1.68 | 1.08 | 0.85 | 0.52 | 0.29 | |
| Working capital | 21.87M | 15.32M | 21.71M | 13.13M | 68.3M | |
| Tangible asset value | 23.08M | 16.65M | 13.86M | 9.34M | 6.08M | |
| Net current asset value | 21.78M | 15.26M | 12.28M | 7.43M | 4.33M | |
| Invested capital | 0.01 | 0.02 | 0.02 | 0.05 | 0.06 | |
| Average receivables | 1.09M | 968.5K | 834K | 514.5K | 104K | |
| Average payables | 4.2M | 2.77M | 2.86M | 3.5M | 3.24M | |
| Average inventory | 0 | -423.5K | -834K | -514.5K | -104K | |
| Days sales outstanding | 0 | 0 | 31.26 | 4.39 | 0 | |
| Days payables outstanding | 2.48K | 830.77 | 2.01K | 2.12K | 1.51K | |
| Days of inventory on hand | 0 | -293.19 | -499.26 | -119.24 | 0 | |
| Receivables turnover | 0 | 0 | 2.88 | 20.5 | 0 | |
| Payables turnover | 0.04 | 0.11 | 0.04 | 0.04 | 0.06 | |
| Inventory turnover | 0 | -0.31 | -0.18 | -0.75 | 0 | |
| ROE | -0.37 | -0.5 | -0.29 | -0.6 | -0.72 | |
| Capex per share | 0 | -0.01 | -0.01 | -0.03 | 0 |
IMNM Frequently Asked Questions
What is Immunome, Inc. stock symbol ?
Immunome, Inc. is a US stock , located in Exton of Pa and trading under the symbol IMNM
What is Immunome, Inc. stock quote today ?
Immunome, Inc. stock price is $15.72 today.
Is Immunome, Inc. stock public?
Yes, Immunome, Inc. is a publicly traded company.
Company Profile
- Volume Average 747.88K
- Market Capitalization 879.38M
- Employee 37
- CEO Dr. Clay B. Siegall Ph.D.
- Headquarters Exton,PA,US
- IPO Date 2020-10-02
-
Website
https://immunome.com 
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
